CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,195 enrolled
Drug / intervention
emtricitabine/tenofovirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03902418
NCT03902418N/ACompleted
CompareCT.gov

Evaluation of Pre-Exposure Prophylaxis (PrEP) Initiation, Retention, and Adherence in Pregnant and Breastfeeding Women

University of California, Los Angeles·observational·Posted Apr 4, 2019·Updated Oct 23, 2024

In Brief

An observational study evaluating emtricitabine/tenofovir for HIV-I Infection. Completed, enrolled 1,195 participants across 1 site.

Detailed Summary

The investigators will conduct an observational cohort study in 1200 pregnant women who will be recruited at the first antenatal care (ANC) visit from the Gugulethu and one additional facility in the Klipfontein-Mitchell's Plain subdistrict of the Metro Region (to be identified in conjunction with provincial and local health authorities) Midwife Obstetric Units in Cape Town (n=600 pregnant women per site). The enrolled women will be followed through 12-months post-delivery.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-I Infection
CountriesSouth Africa
CollaboratorsUniversity of Cape Town

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedApr 4, 2019
Enrollment StartJul 1, 2019
Primary CompletionJun 30, 2024
Study CompletionSep 30, 2024
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 7.2 years ago

Interventions

emtricitabine/tenofovirdrug

Women recruited at ante-natal clinics, counseled about PrEP, and provided medication and follow up if desired